Vanguard Capital Management
CTNM

Vanguard Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Vanguard Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.7M Buy
1,321,356
+107,183
+9% +$1.41M ﹤0.01% 2411
2026
Q1 		$15.9M Buy
+1,214,173
New +$16.3M ﹤0.01% 2471

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Vanguard Capital Management's CTNM Position: Q2 2026 in Review

Vanguard Capital Management increased its Contineum Therapeutics (CTNM) stake by 8.8% in Q2 2026, buying an estimated $1.41M and bringing the position to 1,321,356 shares worth $21.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2411.

Vanguard Capital Management first reported a position in CTNM in Q1 2026 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Vanguard Capital Management held 1,321,356 shares of Contineum Therapeutics worth $21.7M as of Q2 2026.
  • Vanguard Capital Management bought 107,183 Contineum Therapeutics shares in Q2 2026, an estimated $1.41M.
  • Contineum Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2411 holding.
  • Vanguard Capital Management first reported a position in Contineum Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.